Replies to post #156935 on Biotech Values

[Hedge Starz]

I want your opinion on a BioTech play that has recaptured my investment interest significantly. The ticker is $VSTA and their Novel Strategy can be found on their website here - http://www.vistagen.com/?page_id=20
News is here including FUNDING and Pipeline News - http://finance.yahoo.com/q?s=vsta&ql=1


Pipeline Stages and Schedules are here - http://www.vistagen.com/?page_id=11

The Market Cap is under $12MIL http://www.otcmarkets.com/stock/VSTA/company-info Leaving a HUGE Upside if they can Achieve SOME level of success with their plans.

Their strategy can SAVE Previous Drug Applicants that were shelved, and they have their own product lines as well that would not result in Sales Royalties (although that may in fact BE the biggest bread winner for $VSTA in the future).

[jq1234]

I guess MYL picked up what PFE terminated a similar deal with Biocon last year. Refresh my memory, was ever given a reason by anyone?

[DewDiligence]

FDA approves Semglee—MYL’s Lantus biosimilar:

https://www.prnewswire.com/news-releases/mylan-and-biocon-announce-us-fda-approval-of-semglee-insulin-glargine-injection-301074847.html

Favorable judgments on all remaining patent claims asserted by Sanofi against Mylan's insulin glargine products have been obtained. Although Sanofi may seek certain appeals of those judgments, Mylan is confident they will not affect commercialization plans.

Sanofi's total IQVIA sales for the 12 months ending April 30, 2020 were approximately $1.68 billion for Lantus 100 Units/mL Vial and approximately $4.33 billion for Lantus SoloSTAR Pen [i.e. $6.2B in all].

Mylan and Biocon Biologic's insulin glargine has received regulatory approval in more than 45 countries around the world and is the third product approved by FDA through the Mylan-Biocon Biologics collaboration.